Back to search

Peptide record

TPDB92502

LVTX-9-C18 Anticancer standard
19 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB92502
LVTX-9-C18
Anticancer
Cancer-related peptides
CancerPPD 2.0
standard
No
A 19-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.
C-terminal: Amidation N-terminal: CH3-(CH2)16-CO
Sequence
ASIGALIQKAIALIKAKAA-NH2
Physicochemical Analysis
C85H155N23O22
RNDCEHMFPTWYV
A
1851.31
10.84
3
0
13
+3
0.14
1.147
160.00
Mammalian: 4.4 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
2
Residue Composition
number
7
A
0
R
0
N
0
D
0
C
0
E
1
Q
1
G
0
H
4
I
2
L
3
K
0
M
0
F
0
P
1
S
0
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 7 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 1 G: 1 H: 0 I: 4 L: 2 K: 3 M: 0 F: 0 P: 0 S: 1 T: 0 W: 0 Y: 0 V: 0
Chemical Descriptors
19
C85H155N23O22
1851.31
10.84
+3
0.14
1.147
Amidation
L
Linear
CH3-(CH2)16-CO
Anticancer
Synthetic
Evidence Records 4 records
Evidence 1 Activity

Activity

IC50
IC50 = 6.2 ± 1.4 µM
Anticancer
6.2

Target

Lung Cancer
A-549
Lung

Assay & Model

CCK-8 assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2021

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 7.6 ± 1.3 µM
Anticancer
7.6

Target

Breast Cancer
4T1
Breast

Assay & Model

CCK-8 assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2021
Evidence 3 Activity

Activity

IC50
IC50 = 7.0 ± 1.0 µM
Anticancer
7.0

Target

Liver Cancer
HepG-2
Liver

Assay & Model

CCK-8 assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2021
Evidence 4 Activity

Activity

IC50
IC50 = 4.7 ± 1.4 µM
Anticancer
4.7

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

CCK-8 assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2021